The invention provides compounds of formula (I),
1
wherein R
1
represents C
1-4
alkoxy optionally substituted by one or more fluorine atoms; R
2
represents H or C
1-6
alkoxy optionally substituted by one or more fluorine atoms: R
3
represents one or more groups independently selected from H, halogen, C
1-4
alkoxy and CF
3
; in addition, R
2
and one R
3
group may together represent —OCH
2
—, the methylene group being attached to the ortho-position of the pendant phenyl ring; R
4
represents a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent or represents a cyclic group or an open chain group; and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of inter alia benign prostatic hyperplasia.
该发明提供了式(I)的化合物,其中R1代表C1-4烷氧基,该烷氧基可以选择性地被一个或多个
氟原子取代; R2代表H或C1-6烷氧基,该烷氧基可以选择性地被一个或多个
氟原子取代; R3代表H、卤素、C1-4烷氧基和
CF3中的一个或多个基团,此外,R2和一个R3基团可以一起代表- OCH2-,该亚甲基基团附着在悬垂苯环的邻位上; R4代表一个含有1或2个异原子(选自N、O和S)的4、5或6元杂环,该环可以选择性地与苯环或含有1或2个异原子(选自N、O和S)的5或6元杂环融合,整个环系可以选择性地被取代; X代表CH或N; L不存在或代表一个环状基团或开链基团;以及其药学上可接受的盐。式(I)的化合物在治疗良性前列腺增生等方面是有用的。